| For: | Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048 [PMID: 34368325 DOI: 10.12998/wjcc.v9.i21.6041] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i21/6041.htm |
| Number | Citing Articles |
| 1 |
Jiawen Huang, Juan Huang. Immune Checkpoint Inhibitors - New Insights and Recent Progress. 2023; doi: 10.5772/intechopen.107435
|
| 2 |
Valli De Re, Ombretta Repetto, Lara Mussolin, Giulia Brisotto, Caterina Elia, Egesta Lopci, Emanuele S. G. d’Amore, Roberta Burnelli, Maurizio Mascarin. Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma. Frontiers in Cell and Developmental Biology 2022; 10 doi: 10.3389/fcell.2022.965803
|
| 3 |
Yueru Ji, Jing Gao, Tong Wei, Miaowang Hao, Weiwei Qin. Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement. Frontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1699475
|
| 4 |
Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu. Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.866013
|
